Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

7.94
+0.02000.25%
Pre-market: 7.85-0.0900-1.13%04:46 EDT
Volume:819.46K
Turnover:6.60M
Market Cap:692.03M
PE:-3.73
High:8.23
Open:7.90
Low:7.79
Close:7.92
52wk High:36.26
52wk Low:6.65
Shares:87.16M
Float Shares:71.89M
Volume Ratio:0.72
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1289
EPS(LYR):-1.8700
ROE:-52.74%
ROA:-31.82%
PB:1.61
PE(LYR):-4.25

Loading ...

Olema Pharmaceuticals Q1 Net Income USD -53.089 Million

THOMSON REUTERS
·
May 12

Olema grants new-hire stock options for 154,700 shares at $14.32 each

Reuters
·
May 05

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 05

Olema Adds Deal Veteran Prakash Raman To Guide Oncology Partnerships

Simply Wall St.
·
May 03

Olema Pharmaceuticals Signs New Headquarters Lease at Oyster Point

TIPRANKS
·
May 02

Olema Pharmaceuticals Adds Veteran Director to Support Growth

TIPRANKS
·
Apr 30

Olema Pharmaceuticals announces annual shareholder meeting via webcast

Reuters
·
Apr 30

Olema appoints Prakash Raman to board of directors

Reuters
·
Apr 30

Olema Oncology Appoints Prakash Raman, Ph.d., to Board of Directors

THOMSON REUTERS
·
Apr 30

Press Release: Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

Dow Jones
·
Apr 30

Olema Pharmaceuticals (OLMA) Valuation Check After New Palazestrant And OP-3136 Preclinical Results

Simply Wall St.
·
Apr 27

Olema Oncology to present initial clinical data for OP-3136 at ASCO

TIPRANKS
·
Apr 22

Olema to present initial Phase 1 OP-3136 clinical data at ASCO meeting

Reuters
·
Apr 22

Olema Pharmaceuticals (OLMA) Is Up 5.6% After Preclinical Data Highlight Deeper ER Blockade Potential

Simply Wall St.
·
Apr 21

A Look At Olema Pharmaceuticals (OLMA) Valuation After New Preclinical Breast Cancer Data

Simply Wall St.
·
Apr 20

Olema Oncology announces preclinical data for Palazestrant

TIPRANKS
·
Apr 18

Olema says OP-3136 Phase 1 trial enrolls patients in breast cancer study

Reuters
·
Apr 18